Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Relationship Between Sarcopenia (Muscle Loss) and Hormone Therapy in Patients with Early Breast Cancer

The Relationship Between Sarcopenia (Muscle Loss) and Hormone Therapy in Patients with Early Breast Cancer

What Is Sarcopenia?

A reduction or loss of muscle mass is what is meant by sarcopenia, a term that first entered the medical literature in the late 1980s and became a focus of research. In other words, sarcopenia is a decline in lean body mass or muscle mass occurring throughout life. Cancer patients may experience sarcopenia before diagnosis, during treatment, or afterward, and this can also occur in patients with breast cancer.

Sarcopenia in Patients with Breast Cancer

Hormone receptors (HR) are positive in most breast cancer patients. Taking hormone therapy for 5-10 years after surgery as adjuvant (preventive) treatment in women with estrogen receptor- and/or progesterone receptor-positive breast cancer reduces the risk of recurrence and improves survival.

Hormone therapy’s common side effects include musculoskeletal pain (arthralgia), hot flashes, and fatigue; hormone therapies have also been associated with loss of bone density and cardiovascular events.

Experiencing treatment-related side effects can reduce quality of life and treatment adherence. Identifying patients at high risk of these side effects can provide an opportunity for interventions to relieve them.

Although findings are conflicting, the relationships between body composition and breast cancer are well documented. Obesity is associated with increased breast cancer risk, but appears to have a protective effect in premenopausal women and reduce their risk. However, among breast cancer patients, those who are obese have larger tumors, faster disease progression, and a tendency to resist hormonal treatment. Evaluating body composition separately by its components (muscle, fat, and water) in breast cancer patients has been a potentially more informative approach.

Sarcopenia has been associated with increased mortality risk and lower quality of life, as well as poor outcomes in cancer. It can be detected by several methods, including computed tomography (BT) scans and bioelectrical impedance spectroscopy (BIS). BIS and BT images estimate muscle mass, which is then divided by the square of the patient’s height in meters to obtain the skeletal muscle index (SMI). Patients with low SMI are characterized as sarcopenic.

The Relationship Between Hormonal Therapy and Sarcopenia

In patients with both early breast cancer and metastatic breast cancer, sarcopenia has been predicted to worsen survival and has been associated with low chemotherapy completion rates. However, its effect on hormone therapy tolerance has not been well studied to date. This retrospective study, based on analysis of past data, evaluates the relationship between sarcopenia and severe side effects of hormone therapy in women with early breast cancer.

Table 1: Characteristics of Patients Included in the Study

Number of patients

482

Age at Diagnosis

Median (min-max)

<65 years

>65 years

 

61 (29-88)

292

190

Race: White

432

Body mass index

Underweight (< 18.5 kg/m 2 )

Normal (18.5 to < 25 kg/m 2 )

Overweight (25 to < 30 kg/m 2 )

Obese (> 30 kg/m 2 )

 

6 (1%)

134 (28%)

189 (39%)

153 (32%)

Breast cancer stage

Stage 1

Stage 2

Stage 3

 

308 (64%)

125 (26%)

49 (10%)

Comorbidities ≥ 1

 

Hypertension

Diabetes

Severe heart failure

Cirrhosis

Chronic kidney disease stage III

KOAH

Hypothyroidism

Previous breast cancer

Previous cancer

Severe osteoarthritis

Rheumatoid arthritis

Coronary artery disease

Peripheral vascular disease

Osteoporosis

Stroke

360 (74%)

 

232 (48%)

70 (15%)

9 (2%)

5 (1%)

31 (7%)

30 (6%)

80 (17%)

27 (6%)

28 (6%)

89 (18%)

13 (3%)

14 (3%)

5 (1%)

115 (24%)

9 (2%)

Treatment type (patients may have received 2 or more)

Ovarian ablation

Aromatase inhibitor

Tamoksifen

 

23 (5%)

419 (87%)

103 (21%)

Skeletal Muscle Index (SMI) Kg/m 2

Median (min-max)

Sarcopenia < 6.75

 

7.14 (4.84–12.61)

169 (35%)

Early treatment change or discontinuation

61 (13%)

Endocrine toxicity

58 (12%)

13% of participants changed or discontinued treatment because of side effects. Patients with sarcopenia stopped or changed their medication more often because of side effects than those without sarcopenia.

Side Effects of Hormone Therapy

Medical records were reviewed to assess hormone therapy toxicities. Common and severe side effects related to hormone therapy were assessed, including arthralgia, fatigue, hot flashes, nausea/vomiting, bone fracture, and cardiovascular events (acute coronary syndrome, stroke, myocardial infarction, and pulmonary embolism).

The Relationship Between Sarcopenia and Hormone Therapy Toxicity

  • Overall, 12% of patients experienced hormone therapy-related toxicities (arthralgia 8%, bone fracture 0%, cardiovascular events 0.8%, fatigue 1%, hot flashes 3%, nausea/vomiting 0%).
  • People with sarcopenia were more likely to experience hormone therapy-related side effects than those without it.
  • 13% of participants were observed to change or discontinue treatment because of side effects.
  • Patients with sarcopenia stopped or changed their medication more frequently because of side effects than those without sarcopenia.

Conclusion and Commentary

Current guidelines recommend continuing adjuvant hormone therapy for 5 to 10 years. However, prolonged treatment combined with common side effects can make adherence difficult. Approximately 50% of patients reported not taking these drugs as often as prescribed, and approximately 20% stopped endocrine treatment during the first year because of side effects. Sarcopenia was identified as an important risk factor for hormone therapy toxicity and intolerance.

The reasons for reduced hormone therapy tolerance in patients with sarcopenia are their greater frailty and metabolic dysfunction. Patients with sarcopenia have been found to have higher levels of proinflammatory factors, such as fibrinogen, TNF-alfa, IL-6, and C-reactive protein, which can affect drug metabolism, lead to further sarcopenia, and disrupt cancer treatment because of side effects.

A recent study has shown that exercise may improve or reverse sarcopenia among cancer survivors (see Exercise is a cancer drug!). Physical exercise is often recommended to reduce arthralgia and other side effects of endocrine therapy. Exercise has been shown to reduce sarcopenia and improve bone density and quality of life in patients receiving hormone therapy. It would be interesting to investigate whether targeting patients with sarcopenia for a supervised exercise program could reduce hormone therapy toxicity and improve adherence.

*

Below, you can see our infographic poster to better understand breast cancer types and hormone-positive breast cancer:

understanding breast cancer and its treatments hormone-positive her2-positive

Sources

1. Gabriel Aleixo, et al. Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer. Published on researchsquare.com as a preprint and has not yet been peer reviewed.

2. M. Alexander Otto. Sarcopenia Nearly Doubles Risk Women Will Quit Endocrine Therapy - Medscape - May 17, 2022.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Relationship Between Sarcopenia (Muscle Loss) and Hormone Therapy in Patients with Early Breast Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy